Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.4352W HIGH $8.21
Volume
111.12 K
Value Traded
6.15 M
Short % Float
21.89%
-3.52%Week
-30.23%1 Month
-34.31%3 Month
-43.74%6 Month
-55.92%5 Year
-76.5%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
536.03 M
EPS (TTM)
-0.37
P/E Ratio
-
Ent. Value
207.93 M
Total Shares
217.90 M
Float Shares
176.53 M
Insiders
18.99%
Institutions
92.01%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
CTMX Catalyst Timeline
Dated clinical, regulatory and corporate events for CytomX Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for CytomX Therapeutics, Inc.
589Total events
15Upcoming
92Tier-1 (high impact)
2015 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Fast Track DesignationVarseta-MDesignation
FDA granted Fast Track Designation to Varseta-M for R/R mCRC
relapsed/refractory metastatic colorectal cancersource ↗
●Management ChangeCorporate
Expanded executive leadership team with Mamata Gokhale and Alejandra Carvajal
▲Management ChangeCorporate
Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors
●Trial InitiationCX-2051Trial
Initiation of Phase 1 expansion cohort(s) in additional indications
◆Trial InitiationTrial
Phase 1 expansion cohorts initiating in gastric and GEJ cancers
gastric and gastroesophageal junction cancersource ↗
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference Fireside Chat
▲Partnership / LicenseCorporate
Expansion of strategic research collaboration with Regeneron for conditional bispecific therapeutics
cancersource ↗
▲Enrollment CompleteTrial
Enrollment completed in Varseta-M Phase 1 monotherapy study with 113 patients
advanced colorectal cancersource ↗
▲Enrollment Completevarsetatug masetecanTrial
Enrollment of 40 patients in Varseta-M Dose Optimization completed
advanced colorectal cancersource ↗
◆Topline Readoutvarsetatug masetecanClinical Data
Additional Phase 1 Varseta-M data update expected to support monotherapy dose selection and registrational trial design
advanced colorectal cancersource ↗
◆Trial Initiationvarsetatug masetecanTrial
Phase 1/2 Varseta-M chemotherapy combination study to be initiated
colorectal cancersource ↗
◆FDA Feedback Receivedvarsetatug masetecanFDA Meeting
FDA interactions targeted for mid-year to align on registrational trial design
advanced colorectal cancersource ↗
▼Program DiscontinuationCorporate
Astellas chose to not advance remaining preclinical programs under alliance, termination effective Q2 2026
▼Equity OfferingCorporate
Pricing of $250 million underwritten public offering of common stock and pre-funded warrants
▼Equity OfferingCorporate
Announced proposed public offering of $250M common stock and pre-funded warrants
▲Topline Readoutvarsetatug masetecanClinical Data
Positive Phase 1 expansion data announced
late-line metastatic colorectal cancersource ↗
▲Trial Initiationvarsetatug masetecanTrial
Phase 1 Varseta-M combination study with bevacizumab initiated
colorectal cancersource ↗
▼Equity OfferingCorporate
Completed equity follow-on offering with gross proceeds of $250 million
◆Oral PresentationPresentation
Guggenheim Emerging Outlook: Biotech Summit 2026 Fireside Chat
▲Enrollment Milestonevarsetatug masetecanTrial
93 patients enrolled in Phase 1 study
metastatic colorectal cancersource ↗
●Oral PresentationPresentation
CytomX presentation at 44th Annual JP Morgan Healthcare Conference
◆Topline ReadoutCX-2051Clinical Data
CX-2051 Phase 1 data update on track for Q1 2026
colorectal cancer (CRC) and other EpCAM-expressing cancerssource ↗
◆Trial InitiationCX-2051Trial
CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026
colorectal cancer (CRC)source ↗
●Enrollment MilestoneCX-2051Trial
Total Phase 1 study enrollment projected to reach approximately 100 patients
Colorectal Cancersource ↗
▲Trial Initiationvarsetatug masetecanTrial
Phase 1 combination study with bevacizumab initiated
colorectal cancersource ↗
◆Timing GuidanceCX-2051Presentation
Additional Phase 1 data update expected by Q1 2026
advanced colorectal cancersource ↗
◆Oral PresentationPresentation
CytomX Therapeutics to present at Jefferies London Healthcare Conference
◆Poster PresentationCX-801Presentation
CX-801 Phase 1 monotherapy biomarker data poster presentation at SITC 2025
advanced melanomasource ↗
◆Poster PresentationCX-908Presentation
CX-908 preclinical masked T-cell engager poster presentation at SITC 2025
▲Oral PresentationCX-801Presentation
Positive CX-801 Phase 1 monotherapy biomarker data at SITC 2025
melanomasource ↗
◆Management ChangeCorporate
Appointment of Rachael Lester as Senior Vice President, Chief Business Officer
◆Topline ReadoutCX-801Clinical Data
Preliminary tumor biomarker, PD and PK data for CX-801 monotherapy
advanced solid tumors (monotherapy)source ↗
◆Oral PresentationPresentation
Morgan Stanley 23rd Annual Global Healthcare Conference Fireside Chat
◆Oral PresentationPresentation
H.C. Wainwright 27th Annual Global Investment Conference Formal Presentation
◆Enrollment UpdateCX-2051Trial
Enrolled 73 colorectal cancer patients to-date
colorectal cancersource ↗
▲Enrollment MilestoneCX-2051Trial
Initiated CX-2051 dose expansions at 7.2, 8.6, and 10 mg/kg Q3W
advanced colorectal cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How CTMX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-03-31 | CX-2051 (EpCAM PROBODY ADC) | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D30 / 100
Pipeline Score
$326M
Pipeline Value
Overvalued
Valuation Signal
4
Drugs Scored
0.6x
rNPV / MCap
Top 68%
Micro Cap(rank 448 of 658)
Percentile Rank
CytomX Therapeutics, Inc. faces pipeline headwinds (30/100), with $816M risk-adjusted pipeline value, led by CX-2009 in Neoplasms (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CX-2009 Small moleculeCompletedNCT04596150 | Neoplasms | Phase 2 | COMPLETED | 125 | Jun 2, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every CTMX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| varsetatug masetecan Fast Track | advanced colorectal cancer | Phase 1 | 2026-05-07 | 40 total patients across the 8.6 mg/kg Q3W and 10 mg/kg Q3W dosesRead More | CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update - Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY ADC in PaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Ogden ChristopherOfficer (Chief Financial Officer) | Sell | -1,624 295,324 held | $3.05 | 06/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CTMX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Kynam Capital Management, LP | 4.5 % (2.3 %) | 81.39 M | 21.70 M | 44.56% ( 6.69 M) |
CTMX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CTMX ranks across every disease it competes in
Competitive Position is a premium feature
See how CTMX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCTMX News
CTMX▲ +9.2%on this news
CytomX Therapeutics to Present at Upcoming September Investor Conferences
CytomX Therapeutics will present at several investor conferences in September 2026, including the Wells Fargo 21st Annual Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. The company aims to engage with investors and showcase its innovative pipeline of conditionally activated biologics for cancer treatment. Webcasts of the presentations will be available on their website.
Read more →CTMXCytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
CytomX Therapeutics has received FDA Fast Track Designation for Varseta-M, an antibody drug conjugate aimed at treating relapsed/refractory metastatic colorectal cancer. This designation follows promising Phase 1 trial results and highlights the drug's potential to meet significant medical needs. A registrational study is planned to begin in the first half of 2027.
Read more →CTMXCytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
CytomX Therapeutics reported its Q2 2026 financial results, highlighting advancements in its Varseta-M program, including upcoming Phase 1 updates and new combination studies. The company also announced an expanded collaboration with Regeneron and strengthened its leadership team. Despite a decrease in revenue and increased operating expenses, CytomX remains focused on its growth strategy and pipeline development.
Read more →CTMXCytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
CytomX Therapeutics has appointed Alejandra Carvajal as Chief Legal Officer, enhancing its leadership team. Carvajal brings over 20 years of legal experience in biotechnology, having previously held senior roles at Mersana Therapeutics and Momenta Pharmaceuticals. Her expertise is expected to support CytomX's strategic initiatives and advance its PROBODY therapeutic pipeline.
Read more →CTMXCytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
CytomX Therapeutics will report its second quarter financial results on August 6, 2026, after U.S. markets close. A conference call and webcast will follow at 5:00 p.m. ET. The company focuses on developing conditionally activated therapies for cancer, with a pipeline that includes promising candidates like Varseta-M and CX-801.
Read more →CTMXCytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors
CytomX Therapeutics has appointed Dr. Charles Fuchs to its Board of Directors. Dr. Fuchs, an oncology expert with over 30 years of experience, will contribute to advancing CytomX's PROBODY therapeutic pipeline, particularly the Varseta-M program aimed at colorectal cancer. His extensive background in drug development is expected to enhance the company's strategic direction.
Read more →CTMXCytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
CytomX Therapeutics has announced an expansion of its collaboration with Regeneron Pharmaceuticals to develop conditional bispecific cancer therapies. Under this expanded agreement, CytomX will receive a $37 million target selection payment for two new programs. Regeneron has the option to select additional targets, which could result in up to $4 billion in potential milestone payments. The collaboration aims to leverage both companies' technologies to create innovative immunotherapies for challenging cancer types.
Read more →CTMXCytomX Therapeutics to Present at Upcoming June Investor Conferences
CytomX Therapeutics will present at two investor conferences in June 2026, including the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. The company aims to showcase its innovative PROBODY therapeutic platform, which focuses on localized cancer treatments. Management will also be available for one-on-one investor meetings during these events.
Read more →CTMXCytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs
CytomX Therapeutics has appointed Mamata Gokhale, Ph.D., as Senior Vice President of Regulatory Affairs. Dr. Gokhale will lead the company's global regulatory strategy, particularly for its lead program Varseta-M, which is expected to enter a registrational study by mid-2027. Her extensive experience in oncology regulatory affairs is anticipated to enhance CytomX's clinical development efforts.
Read more →CTMXCytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update - Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY ADC in Pa
CytomX Therapeutics announced positive outcomes from the Phase 1 Dose Expansion Study of Varseta-M, targeting advanced colorectal cancer, and is focusing on advancing its clinical development. The company reported Q1 2026 financial results, showing $346.7 million in cash but a significant decrease in revenue compared to the prior year. Multiple trials for Varseta-M and plans for ongoing studies underscore its strategic importance for the company's portfolio. Financial performance highlights increased R&D expenses, reflecting investment in the product's development.
Read more →CTMXCytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
CytomX Therapeutics will report its first quarter financial results on May 7, 2026. Following the announcement, a conference call and webcast will be held to discuss the results. The company focuses on developing conditionally activated biologics for cancer treatment, with a robust pipeline of therapeutic candidates.
Read more →CTMX▼ -19.3%on this news
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
CytomX Therapeutics has announced a public offering of approximately 46 million shares of common stock priced at $5.30 each, aiming to raise $250 million. The funds will primarily support the development of Varseta-M and other pipeline projects. The offering is expected to close on March 19, 2026, pending customary conditions.
Read more →CTMX▲ +44.2%on this newsshared move
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
CytomX Therapeutics announced a public offering of $250 million in common stock and pre-funded warrants. The company plans to use the proceeds for the development of its pipeline programs, including Varseta-M. The offering is contingent on market conditions, and underwriters have an option for an additional $37.5 million in shares.
Read more →CTMX▲ +44.2%on this newsshared move
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update - Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY ADC in Patie
CytomX Therapeutics released its 2025 financial results, highlighting positive outcomes from the Phase 1 dose expansion study of Varseta-M in advanced colorectal cancer. The company aims to engage with the FDA regarding a registrational study design for Varseta-M and has initiated new combination studies. Financially, CytomX reported a revenue decrease due to the conclusion of certain collaborations, while also detailing successful management of expenses. The company maintains a focus on advancing its clinical programs, including the upcoming data from the CX-801 study by 2026.
Read more →CTMX▲ +44.2%on this newsshared move
CytomX’s Varsetatug Masetecan (EpCAM PROBODY ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
CytomX Therapeutics announced positive Phase 1 expansion data for Varsetatug Masetecan (Varseta-M), a novel EpCAM PROBODY ADC aimed at late-line metastatic colorectal cancer. The data reveal confirmed overall response rates of 32% at the 10 mg/kg dosage and progression-free survival rates of 7.1 months. Ongoing safety evaluations showed a 10% Grade 3 diarrhea rate, while the company aims to discuss registrational trial designs with the FDA later this year. Additionally, future combination studies with chemotherapy and other agents are planned.
Read more →CTMX▲ +5.4%on this news
CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
CytomX Therapeutics, Inc. will report its full year 2025 financial results on March 16, 2026, before U.S. markets open. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET. CytomX focuses on developing conditionally activated biologics for cancer treatment, with a promising pipeline including Varseta-M and CX-801.
Read more →CTMX▼ -6.6%on this news
CytomX Therapeutics to Present at Upcoming February Conferences
CytomX Therapeutics announced its participation in two significant conferences in February 2026. The Guggenheim Emerging Outlook: Biotech Summit will take place on February 11, and the World ADC London is scheduled for February 25. These events highlight CytomX's commitment to advancing its innovative cancer therapies.
Read more →CTMXCytomX Therapeutics Announces Business Update and Company Milestones for 2026
CytomX Therapeutics provided business updates and milestones for 2026, highlighting progress in their clinical trials for Varsetatug masetecan (Varseta-M) and CX-801. The company anticipates Phase 1 colorectal cancer expansion data for Varseta-M in Q1 2026 and a combination study with bevacizumab. Additionally, CX-801's combination data with KEYTRUDA is expected by year-end 2026. CytomX's CEO expressed optimism about advancing their promising therapies in their pipeline.
Read more →CTMXCytomX Therapeutics to Present at Upcoming December Investor Conferences
CytomX Therapeutics, Inc. has announced its participation in two upcoming investor conferences in December 2025. The 8th Annual Evercore Healthcare Conference will take place on December 2 in Coral Gables, FL, followed by the Piper Sandler 37th Annual Healthcare Conference on December 4 in New York, NY. During these conferences, CytomX management will engage with investors through presentations and one-on-one meetings.
Read more →About CytomX Therapeutics, Inc.
Headquarters151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE PLUS
Trade the next CTMX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime